Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Certara Inc (CERT)

Certara Inc (CERT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Are These 3 Small Momentum Stocks Setting Up Big Gains?

MINISO, PDF Solutions, and Certara are small stocks with strong price momentum. It’s not unusual for small stocks to show more price momentum than larger peers.

MNSO : 18.19 (-3.24%)
PDFS : 36.37 (+0.83%)
CERT : 14.22 (+2.75%)
RBA : 77.00 (-0.36%)
Xentria Announces Peer Reviewed Publication of Biosimulation Model in Frontiers in Pharmacology Journal

Xentria, Inc., a biotech company focused on developing treatments to address unmet clinical needs, today announced the peer reviewed publication in Frontiers in Pharmacology of a biosimulation model...

CERT : 14.22 (+2.75%)
Why Certara's Shares Rose 37.7% This Week

The company, which helps other companies in their drug development, reported strong third-quarter numbers.

CERT : 14.22 (+2.75%)
Certara, Inc. (CERT) Q2 2022 Earnings Call Transcript

CERT earnings call for the period ending June 30, 2022.

CERT : 14.22 (+2.75%)
Certara Reports Second Quarter 2022 Financial Results

Biosimulation software and services fuel second quarter growth...

CERT : 14.22 (+2.75%)
Certara Introduces Update of Pinnacle 21â„¢ Enterprise and New Pinnacle 21â„¢ Data Exchange Module

New automation, analytics and collaboration features save time and ensure regulatory compliance...

CERT : 14.22 (+2.75%)
Certara Appoints Rosemary Crane as New Independent Board Member

PRINCETON, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of...

CERT : 14.22 (+2.75%)
Certara Introduces New Simcypâ„¢ Discovery Simulator for Early-Stage and Translational Drug Development

Advances lead optimization, first-in-human dose prediction and formulation development...

CERT : 14.22 (+2.75%)
Certara Announces New Versions of Biosimulation Software for Development of Novel Biologics

New capabilities enhance clinical predictability for different compounds across more therapeutic areas...

CERT : 14.22 (+2.75%)
Certara, Inc. (CERT) Q1 2022 Earnings Call Transcript

CERT earnings call for the period ending March 31, 2022.

CERT : 14.22 (+2.75%)

Barchart Exclusives

TDOC Stock Forecast 2025: Can Teladoc Recover from Its Record Lows?
Teladoc Health stock fell to record lows on Wednesday. Can the telehealth stock recover from its slump? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar